Uncategorized
Reading speed suitable outcome measure for lampalizumab trials
MIAMI — Results of the MAHALO study support the use of reading speed as a secondary outcome measure in clinical trials for lampalizumab, a speaker told colleagues here.Lampalizumab (Roche) is a monoclonal antibody fragment that targets factor D and inhibits the progression of geographic atrophy.